Academic publisher Taylor & Francis Group, part of Informa PLC, has acquired independent Open Access (OA) publisher Dove Medical Press for an undisclosed sum.
Dove Medical Press, founded in 2003, publishes primarily in the health sciences, with additional content in science and technology. Of Dove Medical's portfolio of OA journals, 86 are indexed in Clarivate’s Web of Science and 61 in PubMed. Notable titles include OncoTargets and Therapy, Clinical Epidemiology, International Journal of Chronic Obstructive Pulmonary Disease and the International Journal of Nanomedicine.
The deal is a a sign of its "ongoing commitment" to developing both its medical journal and OA programs, according to Taylor & Francis, with the deal taking Informa's OA journal portfolio to over 200 titles, and its total number of journals to more than 2,500.
Financial details were not disclosed but, according to Informa, the transaction is expected to be "modestly accretive to adjusted earnings" in the first full year of ownership and "deliver a return on investment ahead of the cost of capital" within three years.
Ian Bannerman, Taylor & Francis Journals m.d., said: "Taylor & Francis has been purposefully expanding its position in OA over the last few years, to offer the academic community greater flexibility and choice in publishing models. This investment enhances the scale and range of our OA offering to the research community and further enriches the content within our popular Medical program through a range of complementary journals. I am delighted to welcome the Dove Medical Press team, its partners and wider community to our business."
Philip Smith, executive director of Dove Medical Press, emphasised his belief Taylor & Francis was "a good home" for Dove Medical, where it could grow and flourish.
“The aim of Dove Medical Press has been to make original, high quality medical and scientific research openly available," he said. "Over the last 13 years we have worked with a strong and supportive team of authors and editors to realise this goal. I believe that Taylor & Francis Group shares this vision, and for that reason I am confident they will be a good home to nurture and grow the Dove journal portfolio. I am looking forward to seeing them thrive in their new home."